Trade Mark Journal No.2026/018 1 May 2026

UK00004373999 16 April 2026 (5)

R1TX

International priority date claimed: 16 March 2026 (United States of America) (99706076)

Class 5: Pharmaceuticals; medical preparations and substances; Pharmaceutical preparations for the treatment of neurological, immunological, nephrological, oncological, infectious, cardiovascular, vascular, central and peripheral nervous system, autoimmune, endocrinological, gastrointestinal, genetic, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, ocular, neuromuscular, and viral diseases, conditions and disorders.

R1 Therapeutics, Inc.

Representative: CMS Cameron McKenna Nabarro Olswang LLP